Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The structure of lactose permease, stabilized in a periplasmic open conformation by two Gly to Trp replacements (LacYww) and complexed with a nanobody directed against this conformation, provides the highest resolution structure of the symporter. The nanobody binds in a different manner than two other nanobodies made against the same mutant, which also bind to the same general region on the periplasmic side. This region of the protein may represent an immune hotspot. The CDR3 loop of the nanobody is held by hydrogen bonds in a conformation that partially blocks access to the substrate-binding site. As a result, kon and koff for galactoside binding to either LacY or the double mutant complexed with the nanobody are lower than for the other two LacY/nanobody complexes though the Kd values are similar, reflecting the fact that the nanobodies rigidify structures along the pathway. While the wild-type LacY/nanobody complex clearly stabilizes a similar 'extracellular open' conformation in solution, judged by binding kinetics, the complex with wild-type LacY did not yet crystallize, suggesting the nanobody does not bind strongly enough to shift the equilibrium to stabilize a periplasmic side-open conformation suitable for crystallization. However, the similarity of the galactoside binding kinetics for the nanobody-bound complexes with wild type LacY and with LacYWW indicates that they have similar structures, showing that the reported co-structures reliably show nanobody interactions with LacY.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205474PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0232846PLOS

Publication Analysis

Top Keywords

complexed nanobody
8
galactoside binding
8
binding kinetics
8
nanobody
6
lacy
5
conformation
5
diversity kinetics
4
kinetics correlated
4
correlated structure
4
structure nano
4

Similar Publications

Predicting Antibody-Antigen (Ab-Ag) docking and structure-based design represent significant long-term and therapeutically important challenges in computational biology. We present SAGERank, a general, configurable deep learning framework for antibody design using Graph Sample and Aggregate Networks. SAGERank successfully predicted the majority of epitopes in a cancer target dataset.

View Article and Find Full Text PDF

Application of nanobody‑based CAR‑T in tumor immunotherapy (Review).

Int J Mol Med

November 2025

Department of Basic Medical Science, Guangxi Health Science College, Nanning, Guangxi Zhuang Autonomous Region 530023, P.R. China.

Chimeric antigen receptor (CAR) T cell therapy is a type of cellular immunotherapy showing promising clinical effectiveness and high precision. CAR‑T cells express membrane receptors with high specificity, which enable them to identify certain target antigens generated by cancerous cells. The three primary structural elements of the CAR are the extracellular domain, transmembrane domain and cytoplasmic domain.

View Article and Find Full Text PDF

Von Willebrand disease (VWD)-type 1 is a bleeding disorder characterized by a quantitative deficiency of functional von Willebrand factor (VWF). We designed a novel bispecific nanobody, named KB-V13A12, that aims to increase endogenous VWF levels by bridging it to albumin. KB-V13A12 comprises two single-domain antibodies, one targeting VWF and one targeting albumin.

View Article and Find Full Text PDF

A Rapid and Modular Nanobody Assay for Plug-and-Play Antigen Detection.

ACS Synth Biol

September 2025

Department of Biomedical Engineering, Boston University, Boston, Massachusetts 02215, United States.

Rapid and portable antigen detection is essential for managing infectious diseases and responding to toxic exposures, yet current methods face significant limitations. Highly sensitive platforms like the Enzyme-Linked Immunosorbent Assay (ELISA) are time- and cost-prohibitive for point-of-need detection, while portable options like lateral flow assays (LFAs) require systemic overhauls for new targets. Furthermore, the complex infrastructure, high production costs, and extended timelines for assay development constrain the manufacturing of traditional diagnostic platforms in low-resource settings.

View Article and Find Full Text PDF

Despite remarkable advances in cancer therapeutics, conventional treatments still face significant hurdles, including systemic toxicity, poor tumor specificity, multidrug resistance, and suboptimal intracellular delivery. Lipid-based nanocarriers (LBNCs) have emerged as versatile platforms for delivering therapeutic RNA molecules, offering biocompatibility and tunable properties that enhance drug stability and bioavailability. Functionalizing these nanocarriers with antibodies has unlocked new potential for achieving precise tumor targeting, leveraging the overexpression of specific receptors on cancer cells.

View Article and Find Full Text PDF